Female BALB/c wild-type (wt) mice (6–8 weeks) were purchased from Harlan Laboratories, Zeist, The Netherlands. Six to eight weeks old C57BL6/J (wt) and B6.129-Tlr2tm1Kir/J mice (TLR2KO) were purchased from Jackson Laboratories, France. All mice were kept under standard housing conditions at the University of Groningen, The Netherlands. Animal experiments were evaluated and approved by the Committee for

Animal Experimentation of the University of Groningen, The Netherlands, according to the guidelines provided by Dutch Animal Protection Act. Influenza monovalent split vaccines of strain A/Beijing/262/95 (H1N1) and A/Sydney/5/97 (H3N2) were purchased from AdImmune Corp, Taiwan (egg derived, formalin inactivated). The concentration of the Protein Tyrosine Kinase inhibitor haemagglutinin (HA) in the vaccine was determined using the single radial immunodiffusion this website assay. The standard BLP-SV vaccines consisted of influenza monovalent SV containing 5 µg HA antigen mixed with BLPs (0.15 mg dry-weight). BLPs were prepared as described before [13] and [14]. BLPs were stored at -80 °C until use. BLPs and SV, were

mixed just prior to i.n. administration. All i.n. vaccine doses were delivered in a final volume of 10 µl of PBS. Mice to be i.n. immunized were lightly anaesthetized with 2.5%, v/v, isoflurane over oxygen (0.8 L/min). Once anaesthetized, the mice were vaccinated i.n. every 10 days with 10 µl of sterile PBS containing BLP-SV (BLPs mixed with the influenza A strain (A/Beijing/262/95 (H1N1)) or SV alone and sacrificed at day

34 of the experiment. Mice were vaccinated i.n. 3 times on day 0, 14 and 28 with 10 µl of sterile PBS containing BLP-SV (BLPs mixed with the influenza A strain (A/Sydney/5/97(H3N2)) or SV alone and sacrificed at day 42 of the experiment. SV without BLPs was administered i.m. in 50 µl of PBS as a positive control for the immunogenicity of the antigenic materials. Blood was collected via puncture of the orbital plexus for antibody measurements and the mice were sacrificed on day 34 or 42 via exsanguination by heart puncture under O2/isoflurane anaesthesia. Subsequently, nasal, lung and vaginal washes were conducted for SIgA antibody measurements. For nasal and lung lavages, 1 ml PBS that contained Roche Rutecarpine “complete” protease inhibitor (according to manufacturer’s description) was used. The tube containing the lavage fluid was placed on ice and centrifuged at 300–400 × g for 5 min at 4 °C and supernatants were collected. Vaginal lavages were conducted by repeated pipetting of 0.2 ml of PBS supplemented with Roche “complete” protease inhibitor. All lavage samples were stored at -20 °C. ELISA was performed as previously described [27]. Briefly, ELISA plates (Greiner, The Netherlands) were coated overnight at 4 °C with influenza monovalent split vaccines of strain A/Sidney/5/97 H3N2 or A/Beijing/262/95 H1N1 (AdImmune). The plates were washed twice and blocked in 200 µl of a 2.5% solution of Protifar Plus (Nutricia™) in coating buffer (0.